MARKET

ONTX

ONTX

Onconova
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.56
+0.49
+6.93%
Pre Market: 8.18 +0.62 +8.20% 05:59 06/15 EDT
OPEN
7.15
PREV CLOSE
7.07
HIGH
7.74
LOW
7.04
VOLUME
2.23K
TURNOVER
--
52 WEEK HIGH
28.95
52 WEEK LOW
2.850
MARKET CAP
119.30M
P/E (TTM)
-3.7520
1D
5D
1M
3M
1Y
5Y
Thinking about buying stock in Irving Resources, Soligenix, Exela Technologies, Soleno Therapeutics, or Onconova Therapeutics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IRV, SNGX, XELA, SLNO, and ONTX.
PR Newswire - PRF · 4d ago
IVR, RH, ASAN and EDU among premarket gainers
Medley Management (MDLY) +79%.Orbsat Corp (OSAT) +38%.Sphere 3D Corp. (ANY) +30%.Xinyuan Real Estate (XIN) +26% after announcing the completion of five newly constructed properties.Zivo Bioscience (ZIVO) +21%.China HGS Real Estate (HGSH)
Seekingalpha · 4d ago
Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium
NEWTOWN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members ...
GlobeNewswire · 4d ago
Onconova Therapeutics Stock Gives Every Indication Of Being Significantly Overvalued
GuruFocus News · 06/06 22:00
Onconova Therapeutics, Inc. (ONTX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks.com · 06/04 16:00
Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital
NEWTOWN, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova...
GlobeNewswire · 06/03 12:00
Onconova Therapeutics names Mark Gelder as chief medical officer
Onconova Therapeutics ([[ONTX]] -4.8%) announces the appointment of Mark Gelder as the company's chief medical officer ((CMO)), effective as of June 14, 2021.Gelder has more than 35 years of experience in clinical development,
Seekingalpha · 06/01 15:04
52 Biggest Movers From Yesterday
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive immuno-oncology RNA therapy for the treatment of multiple cancer...
Benzinga · 05/25 08:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONTX. Analyze the recent business situations of Onconova through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONTX stock price target is 35.50 with a high estimate of 60.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 3.64M
% Owned: 23.06%
Shares Outstanding: 15.78M
TypeInstitutionsShares
Increased
16
568.01K
New
28
763.65K
Decreased
5
42.80K
Sold Out
4
18.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.15%
Pharmaceuticals & Medical Research
+0.13%
Key Executives
Chairman/Director
James Marino
President/Chief Executive Officer/Director
Steven Fruchtman
Chief Financial Officer
Mark Guerin
Vice President/General Counsel
Abraham Oler
Director
Henry Bienen
Director
Jerome Groopman
Director
Viren Mehta
Director
Terri Shoemaker
Director
Jack Stover
Director
Anne VanLent
No Data
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONTX stock methods without spending real money on the virtual paper trading platform.